Sector News

Thomson Reuters spotlights the R&D trends behind 2016's top blockbusters

February 4, 2016
Life sciences

Last year Thomson Reuters started 2015 by pegging 11 likely blockbusters in the late-stage pipeline. This year, that number has shrunk to 7, as rare diseases and new drug cocktails continue to grab the attention of the most ambitious players in the industry.

Thomson Reuters’ report, which follows a similar effort by EvaluatePharma, taps these 7 programs as the ones most likely to earn more than $1 billion in revenue by 2020. And Gilead, which has been earning huge rewards from its new hep C drug franchise, stands to be the single biggest single gainer on that short list with two new cocktails for HIV.

• Obeticholic acid (OCA) for liver disease from Intercept and Sumitomo Dainippon — 2020: $2.6 billion.
• Emtricitabine + tenofovir alafenamide (F/TAF) for HIV-1 from Gilead — 2020: $2 billion.
• Tenofovir alafenamide + emtricitabine + rilpivirine (R/F/TAF), for HIV-1 from Gilead — 2020: $1.6 billion.
• MK-5172A (grazoprevir + elbasvir) for hep C from Merck — 2020: $1.5 billion.
• Venetoclax for chronic lymphocytic leukemia from AbbVie/Roche — 2020: $1.5 billion
• Nuplazid (pimavanserin) for Parkinson’s from Acadia Pharmaceuticals — 2020: $1.4 billion
• Uptravi (selexipag) for pulmonary arterial hypertension from Nippon Shinyaku Co and Actelion — 2020: $1.3 billion.

The analysts at Thomson Reuters zeroed in on the growing importance of orphan drugs like OCA and venetoclax, which accounted for close to half of all the record number of drugs approved in 2015. With development times shortening and incentives growing for the orphan class, you can expect this trend to remain strong for some time.

The new report also highlights the importance of new, easier cocktail therapies for HIV and hepatitis C in the pipeline.

Another trend that will stay front and center: The criticism of high drug prices can only intensify. Gilead started the furor with its pricing on Sovaldi, and companies are expected to turn to new pricing models that may help moderate the backlash. This report highlighted Novartis’ suggestions on creating a success-driven pricing model for the heart failure drug Entresto as one initiative that’s likely to breed more price experimentation.

– here’s the report

By John Carroll

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.